P555 Switching from intravenous vedolizumab to subcutaneous maintains clinical remission even in intensified patients with Inflammatory Bowel Disease. One year follow-up
Andres Pascual, L, Arias García, L, Saiz Chumillas, R M, Chivato Martín-Falquina, I, Sicilia Aladren, B
Published in Journal of Crohn's and colitis (24.01.2024)
Published in Journal of Crohn's and colitis (24.01.2024)
Get full text
Journal Article
P617 Switching from an intensified regimen of infliximab to a subcutaneous standard dose in adults with Inflammatory Bowel Disease: our experience in a tertiary hospital
Chivato Martín Falquina, I, Saiz Chumillas, R M, Arias Garcia, L, Vicente González, B, Revilla Cuesta, N, Alba Hernández, L, Andrés Pascual, L, Sicilia Aladrén, B
Published in Journal of Crohn's and colitis (21.01.2022)
Published in Journal of Crohn's and colitis (21.01.2022)
Get full text
Journal Article